CXCR7

CXCR7

A gene on chromosome 2q37.3 that encodes a member of the G protein-coupled receptor family which is a receptor for CXCL12/SDF1 and a coreceptor with CXCR4 for some HIV isolates.
References in periodicals archive ?
25-fold (Supplementary Table S4, Figure 4), while 46 cytokine receptors (CSF3R, CXCR7, IL-17RA, IL-18R1, IL-1R1, IL-1R2, IL-20RA, IL-21R, IL-2RG, IL-4I1, IL-5RA, IL-7R, IL-9R, LILRB3, TGFBR1, TLR1, TLR15, TLR21, TLR5, TLR6, TLR7, TNFRSF13B, TNFRSF13C, TNFRSF1B, TRAT1, XCR1, etc.
CXCL12, CXCR4 and CXCR7 expression in brain metastases.
Work by another lab called Klein's attention to CXCR7, a receptor that binds to CXCL12.
These programs include a novel drug targeting the chemokine receptor CCR2, which has just successfully completed a Phase 2 clinical trial and a cancer program targeting the receptor CXCR7, which was discovered by ChemoCentryx scientists.
The CXCL12 ligand works through 7-transmembrane receptors CXCR4 and CXCR7 to affect changes in a variety of neural cells and alter migration.
CXCR7 is a novel chemokine receptor whose function was discovered and characterized by ChemoCentryx.
The CXCL12 / CXCR4 / CXCR7 axis has been shown to play a role in stem cell mobilization, vasculogenesis, tumor growth and metastasis.
By constructing synthetic 3D mimics of the ligand binding-site on CXCR7 it has induced functional antibodies against the formerly intractable GPCR target CXCR7.
NOX-A12 is the only anti-cancer agent in active clinical development that neutralizes CXCL12, thereby resulting in a complete block of CXCL12 signaling through its two receptors, CXCR4 and CXCR7.
These data represent a significant scientific finding with potentially profound clinical implications, providing the first demonstration that CXCR7 -- which was discovered as well as characterized by ChemoCentryx using our proprietary EnabaLink Drug Discovery engine -- is fundamental to cancer growth and progression and therefore, an important new cancer target," said Thomas J.
NOX-A12 is the only anti-cancer agent in active clinical development that neutralizes the CXCL12 ligand, thereby resulting in a complete block of CXCL12 signaling through its two receptors, CXCR4 and CXCR7.
Leading cancer researchers have demonstrated that a high level of CXCR4 and CXCR7 expression in cancer cells is correlated to tumor progression, high metastasis rate and low patient survival rate.